Core Scientific, Inc./tx
For the period ended Jun 30, 2026. Filed Jul 28, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 28, 2026
CORZ$13.13+3.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Condensed Consolidated Statements of Changes in Stockholders’ Deficit
(Unaudited, in thousands)
| Common Stock · AdditionalPaid-In Capital · AccumulatedDeficit · TotalStockholders’Deficit | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balance at March 31, 2026 | 316,949 | $3 | $3,188,202 | $(4,493,891) | $(1,305,686) |
| Net loss | — | — | — | (1,155,310) | (1,155,310) |
| Stock-based compensation | — | — | 18,759 | — | 18,759 |
| Restricted stock awards issued | 2,065 | — | 6,073 | — | 6,073 |
| Restricted stock awards withheld for tax withholding obligations | (915) | — | (17,724) | — | (17,724) |
| Exercise of warrants | 1,488 | — | 34,532 | — | 34,532 |
| Balance at June 30, 2026 | 319,587 | $3 | $3,229,842 | $(5,649,201) | $(2,419,356) |
| Balance at March 31, 2025 | 299,087 | $3 | $2,973,015 | $(3,281,836) | $(308,818) |
| Net loss | — | — | — | (936,799) | (936,799) |
| Stock-based compensation | — | — | 24,346 | — | 24,346 |
| Restricted stock awards issued | 1,499 | — | — | — | — |
| Equity issuance costs | — | — | (21) | — | (21) |
| Exercise of warrants | 2,560 | — | 29,305 | — | 29,305 |
| Balance at June 30, 2025 | 303,146 | $3 | $3,026,645 | $(4,218,635) | $(1,191,987) |
| Common Stock · AdditionalPaid-In Capital · AccumulatedDeficit · TotalStockholders’Deficit | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balance at December 31, 2025 | 314,231 | $3 | $3,183,960 | $(4,146,703) | $(962,740) |
| Net loss | — | — | — | (1,502,498) | (1,502,498) |
| Stock-based compensation | — | — | 37,146 | — | 37,146 |
| Restricted stock awards issued | 5,755 | — | 6,728 | — | 6,728 |
| Restricted stock awards withheld for tax withholding obligations | (2,274) | — | (39,375) | — | (39,375) |
| Exercise of warrants | 1,875 | — | 41,383 | — | 41,383 |
| Balance at June 30, 2026 | 319,587 | $3 | $3,229,842 | $(5,649,201) | $(2,419,356) |
| Balance at December 31, 2024 | 292,606 | $3 | $2,915,035 | $(3,858,087) | $(943,049) |
| Net loss | — | — | — | (360,548) | (360,548) |
| Stock-based compensation | — | — | 40,751 | — | 40,751 |
| Restricted stock awards issued | 4,479 | — | (50) | — | (50) |
| Equity issuance costs | — | — | (21) | — | (21) |
| Exercise of warrants | 6,061 | — | 70,930 | — | 70,930 |
| Balance at June 30, 2025 | 303,146 | $3 | $3,026,645 | $(4,218,635) | $(1,191,987) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.